Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Jan 24;9(1):11.
doi: 10.1186/1465-9921-9-11.

The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children

Stephen B Lambert  1 , Kelly M Allen, Robert C Carter, Terence M Nolan
Affiliations
Comparative Study

The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children

Stephen B Lambert et al. Respir Res. .

Abstract

Background: Acute respiratory illnesses (ARIs) during childhood are often caused by respiratory viruses, result in significant morbidity, and have associated costs for families and society. Despite their ubiquity, there is a lack of interdisciplinary epidemiologic and economic research that has collected primary impact data, particularly associated with indirect costs, from families during ARIs in children.

Methods: We conducted a 12-month cohort study in 234 preschool children with impact diary recording and PCR testing of nose-throat swabs for viruses during an ARI. We used applied values to estimate a virus-specific mean cost of ARIs.

Results: Impact diaries were available for 72% (523/725) of community-managed illnesses between January 2003 and January 2004. The mean cost of ARIs was AU$309 (95% confidence interval $263 to $354). Influenza illnesses had a mean cost of $904, compared with RSV, $304, the next most expensive single-virus illness, although confidence intervals overlapped. Mean carer time away from usual activity per day was two hours for influenza ARIs and between 30 and 45 minutes for all other ARI categories.

Conclusion: From a societal perspective, community-managed ARIs are a significant cost burden on families and society. The point estimate of the mean cost of community-managed influenza illnesses in healthy preschool aged children is three times greater than those illnesses caused by RSV and other respiratory viruses. Indirect costs, particularly carer time away from usual activity, are the key cost drivers for ARIs in children. The use of parent-collected specimens may enhance ARI surveillance and reduce any potential Hawthorne effect caused by compliance with study procedures. These findings reinforce the need for further integrated epidemiologic and economic research of ARIs in children to allow for comprehensive cost-effectiveness assessments of preventive and therapeutic options.

PubMed Disclaimer

References

    1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494. doi: 10.1001/archinte.163.4.487. - DOI - PubMed
    1. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J. 2003;22:S207–210. - PubMed
    1. Principi N, Esposito S, Gasparini R, Marchisio P, Crovari P. Burden of influenza in healthy children and their households. Arch Dis Child. 2004;89:1002–1007. doi: 10.1136/adc.2003.045401. - DOI - PMC - PubMed
    1. Esposito S, Gasparini R, Bosis S, Marchisio P, Tagliabue C, Tosi S, Bianchi C, Crovari P, Principi N. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect. 2005;11:933–936. doi: 10.1111/j.1469-0691.2005.01270.x. - DOI - PubMed
    1. Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, Bianchi C, Colombo GL, Principi N. Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine. 2006;24:629–635. doi: 10.1016/j.vaccine.2006.03.059. - DOI - PubMed

Publication types